{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:21:14Z","timestamp":1778156474864,"version":"3.51.4"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K01 DA036751"],"award-info":[{"award-number":["K01 DA036751"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA044015"],"award-info":[{"award-number":["R01 DA044015"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["104036\/Z\/14\/Z"],"award-info":[{"award-number":["104036\/Z\/14\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s40263-018-0513-9","type":"journal-article","created":{"date-parts":[[2018,4,5]],"date-time":"2018-04-05T03:18:29Z","timestamp":1522898309000},"page":"305-320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Pharmacogenetics of Opioid Use Disorder Treatment"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9461-1256","authenticated-orcid":false,"given":"Richard C.","family":"Crist","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toni-Kim","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wade H.","family":"Berrettini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,5]]},"reference":[{"issue":"1","key":"513_CR1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1176\/appi.ajp.2015.15020262","volume":"173","author":"KT Brady","year":"2016","unstructured":"Brady KT, McCauley JL, Back SE. Prescription opioid misuse, abuse, and treatment in the united states: an update. Am J Psychiatry. 2016;173(1):18\u201326.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"513_CR2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/M17-0865","volume":"167","author":"B Han","year":"2017","unstructured":"Han B, et al. Prescription opioid use, misuse, and use disorders in US adults: 2015 National survey on drug use and health. Ann Intern Med. 2017;167(5):293\u2013301.","journal-title":"Ann Intern Med"},{"issue":"2","key":"513_CR3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.7326\/0003-4819-146-2-200701160-00006","volume":"146","author":"BA Martell","year":"2007","unstructured":"Martell BA, et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med. 2007;146(2):116\u201327.","journal-title":"Ann Intern Med"},{"issue":"1\u20132","key":"513_CR4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.drugalcdep.2013.01.007","volume":"132","author":"CM Jones","year":"2013","unstructured":"Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers\u2014United States, 2002\u20132004 and 2008\u20132010. Drug Alcohol Depend. 2013;132(1\u20132):95\u2013100.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"513_CR5","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1526-4637.2011.01075.x","volume":"12","author":"HG Birnbaum","year":"2011","unstructured":"Birnbaum HG, et al. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12(4):657\u201367.","journal-title":"Pain Med"},{"issue":"10","key":"513_CR6","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/MLR.0000000000000625","volume":"54","author":"CS Florence","year":"2016","unstructured":"Florence CS, et al. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care. 2016;54(10):901\u20136.","journal-title":"Med Care"},{"issue":"5","key":"513_CR7","doi-asserted-by":"crossref","first-page":"e0177323","DOI":"10.1371\/journal.pone.0177323","volume":"12","author":"R Jiang","year":"2017","unstructured":"Jiang R, et al. The societal cost of heroin use disorder in the United States. PLoS One. 2017;12(5):e0177323.","journal-title":"PLoS One"},{"key":"513_CR8","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s12888-016-0909-3","volume":"16","author":"SP Novak","year":"2016","unstructured":"Novak SP, et al. Nonmedical use of prescription drugs in the European Union. BMC Psychiatry. 2016;16:274.","journal-title":"BMC Psychiatry"},{"key":"513_CR9","unstructured":"United Nations Office on Drugs and Crime. World Drug Report 2017, United Nations publication. ISBN: 978-92-1-148291-1"},{"key":"513_CR10","doi-asserted-by":"publisher","unstructured":"Mattick RP, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207. https:\/\/doi.org\/10.1002\/14651858.CD002207.pub2.","DOI":"10.1002\/14651858.CD002207.pub2"},{"issue":"8","key":"513_CR11","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/add.12536","volume":"109","author":"L Degenhardt","year":"2014","unstructured":"Degenhardt L, et al. The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. Addiction. 2014;109(8):1306\u201317.","journal-title":"Addiction"},{"key":"513_CR12","doi-asserted-by":"publisher","unstructured":"Gowing L, et al. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011;(8):CD004145. https:\/\/doi.org\/10.1002\/14651858.CD004145.pub4.","DOI":"10.1002\/14651858.CD004145.pub4"},{"issue":"4","key":"513_CR13","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2174\/1570159043359477","volume":"2","author":"K Lutfy","year":"2004","unstructured":"Lutfy K, Cowan A. Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol. 2004;2(4):395\u2013402.","journal-title":"Curr Neuropharmacol"},{"key":"513_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/SAR.S45585","volume":"6","author":"M Soyka","year":"2015","unstructured":"Soyka M. New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone. Subst Abuse Rehabil. 2015;6:1\u201314.","journal-title":"Subst Abuse Rehabil"},{"key":"513_CR15","doi-asserted-by":"publisher","unstructured":"Minozzi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2011;(4):CD001333. https:\/\/doi.org\/10.1002\/14651858.CD001333.pub4.","DOI":"10.1002\/14651858.CD001333.pub4"},{"issue":"10","key":"513_CR16","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1046\/j.1360-0443.2002.00217.x","volume":"97","author":"U Kirchmayer","year":"2002","unstructured":"Kirchmayer U, et al. A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. Addiction. 2002;97(10):1241\u20139.","journal-title":"Addiction"},{"issue":"4","key":"513_CR17","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1360-0443.2006.01369.x","volume":"101","author":"BA Johansson","year":"2006","unstructured":"Johansson BA, Berglund M, Lindgren A. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction. 2006;101(4):491\u2013503.","journal-title":"Addiction"},{"issue":"9","key":"513_CR18","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/add.12208","volume":"108","author":"E Krupitsky","year":"2013","unstructured":"Krupitsky E, et al. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction. 2013;108(9):1628\u201337.","journal-title":"Addiction"},{"issue":"9776","key":"513_CR19","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","volume":"377","author":"E Krupitsky","year":"2011","unstructured":"Krupitsky E, et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506\u201313.","journal-title":"Lancet"},{"issue":"14","key":"513_CR20","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","volume":"41","author":"CB Eap","year":"2002","unstructured":"Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153\u201393.","journal-title":"Clin Pharmacokinet"},{"issue":"2 Suppl","key":"513_CR21","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0376-8716(03)00058-9","volume":"70","author":"CN Chiang","year":"2003","unstructured":"Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003;70(2 Suppl):S39\u201347.","journal-title":"Drug Alcohol Depend"},{"issue":"2\u20133","key":"513_CR22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.drugalcdep.2007.06.007","volume":"91","author":"EF McCance-Katz","year":"2007","unstructured":"McCance-Katz EF, et al. Interaction between buprenorphine and atazanavir or atazanavir\/ritonavir. Drug Alcohol Depend. 2007;91(2\u20133):269\u201378.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"513_CR23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","volume":"109","author":"YI Hser","year":"2014","unstructured":"Hser YI, et al. Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79\u201387.","journal-title":"Addiction"},{"issue":"1","key":"513_CR24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1360-0443.1998.931738.x","volume":"93","author":"DD Brewer","year":"1998","unstructured":"Brewer DD, et al. A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction. 1998;93(1):73\u201392.","journal-title":"Addiction"},{"key":"513_CR25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jsat.2015.05.001","volume":"57","author":"RE Clark","year":"2015","unstructured":"Clark RE, et al. Risk factors for relapse and higher costs among medicaid members with opioid dependence or abuse: opioid agonists, comorbidities, and treatment history. J Subst Abuse Treat. 2015;57:75\u201380.","journal-title":"J Subst Abuse Treat"},{"issue":"Suppl 1","key":"513_CR26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/add.12780","volume":"110","author":"W Yin","year":"2015","unstructured":"Yin W, et al. Factors associated with depression and anxiety among patients attending community-based methadone maintenance treatment in China. Addiction. 2015;110(Suppl 1):51\u201360.","journal-title":"Addiction"},{"issue":"1","key":"513_CR27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1521-0391.2013.12074.x","volume":"23","author":"M Ferri","year":"2014","unstructured":"Ferri M, et al. Predictive factors for relapse in patients on buprenorphine maintenance. Am J Addict. 2014;23(1):62\u20137.","journal-title":"Am J Addict"},{"key":"513_CR28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jsat.2016.12.010","volume":"74","author":"ZM Weinstein","year":"2017","unstructured":"Weinstein ZM, et al. Long-term retention in Office Based Opioid Treatment with buprenorphine. J Subst Abuse Treat. 2017;74:65\u201370.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"513_CR29","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1472-8206.1999.tb00009.x","volume":"13","author":"R Bouer","year":"1999","unstructured":"Bouer R, et al. The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. Fundam Clin Pharmacol. 1999;13(4):494\u2013500.","journal-title":"Fundam Clin Pharmacol"},{"issue":"3","key":"513_CR30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1211\/0022357022782","volume":"56","author":"M Rodriguez","year":"2004","unstructured":"Rodriguez M, et al. Effect of P-glycoprotein inhibition on methadone analgesia and brain distribution in the rat. J Pharm Pharmacol. 2004;56(3):367\u201374.","journal-title":"J Pharm Pharmacol"},{"issue":"6","key":"513_CR31","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.clpt.2006.09.011","volume":"80","author":"JK Coller","year":"2006","unstructured":"Coller JK, et al. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther. 2006;80(6):682\u201390.","journal-title":"Clin Pharmacol Ther"},{"issue":"14","key":"513_CR32","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1093\/hmg\/ddn122","volume":"17","author":"O Levran","year":"2008","unstructured":"Levran O, et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet. 2008;17(14):2219\u201327.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"513_CR33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1067\/mcp.2001.117412","volume":"70","author":"RB Kim","year":"2001","unstructured":"Kim RB, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70(2):189\u201399.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"513_CR34","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.2217\/pgs.11.96","volume":"12","author":"CC Hung","year":"2011","unstructured":"Hung CC, et al. Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics. 2011;12(11):1525\u201333.","journal-title":"Pharmacogenomics"},{"issue":"6","key":"513_CR35","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.clpt.2006.09.012","volume":"80","author":"S Crettol","year":"2006","unstructured":"Crettol S, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther. 2006;80(6):668\u201381.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"513_CR36","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s40262-016-0415-2","volume":"55","author":"C Csajka","year":"2016","unstructured":"Csajka C, et al. Population genetic-based pharmacokinetic modeling of methadone and its relationship with the QTc interval in OPIOID-DEPENDENT PATIENTS. Clin Pharmacokinet. 2016;55(12):1521\u201333.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"513_CR37","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/sj.clpt.6100305","volume":"83","author":"S Crettol","year":"2008","unstructured":"Crettol S, et al. No influence of ABCB1 haplotypes on methadone dosage requirement. Clin Pharmacol Ther. 2008;83(5):668\u20139 (author reply 669\u201370).","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"513_CR38","doi-asserted-by":"crossref","first-page":"e19527","DOI":"10.1371\/journal.pone.0019527","volume":"6","author":"F Fonseca","year":"2011","unstructured":"Fonseca F, et al. Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS One. 2011;6(5):e19527.","journal-title":"PLoS One"},{"issue":"6","key":"513_CR39","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/bcp.12576","volume":"79","author":"S Mouly","year":"2015","unstructured":"Mouly S, et al. Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity. Br J Clin Pharmacol. 2015;79(6):967\u201377.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"513_CR40","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1556-4029.2009.01278.x","volume":"55","author":"A Buchard","year":"2010","unstructured":"Buchard A, et al. Postmortem blood concentrations of R- and S-enantiomers of methadone and EDDP in drug users: influence of co-medication and p-glycoprotein genotype. J Forensic Sci. 2010;55(2):457\u201363.","journal-title":"J Forensic Sci"},{"key":"513_CR41","first-page":"741403","volume":"2013","author":"HY Lee","year":"2013","unstructured":"Lee HY, et al. Moving toward personalized medicine in the methadone maintenance treatment program: a pilot study on the evaluation of treatment responses in Taiwan. Biomed Res Int. 2013;2013:741403.","journal-title":"Biomed Res Int"},{"issue":"18","key":"513_CR42","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.2217\/pgs-2017-0072","volume":"18","author":"R Luo","year":"2017","unstructured":"Luo R, et al. Impact of SNP-SNP interaction among ABCB1, ARRB2, DRD1 and OPRD1 on methadone dosage requirement in Han Chinese patients. Pharmacogenomics. 2017;18(18):1659\u201370.","journal-title":"Pharmacogenomics"},{"issue":"1","key":"513_CR43","doi-asserted-by":"crossref","first-page":"e86114","DOI":"10.1371\/journal.pone.0086114","volume":"9","author":"BB Dennis","year":"2014","unstructured":"Dennis BB, et al. Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis. PLoS One. 2014;9(1):e86114.","journal-title":"PLoS One"},{"key":"513_CR44","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.drugalcdep.2014.10.014","volume":"145","author":"G Bart","year":"2014","unstructured":"Bart G, et al. Ethnic and genetic factors in methadone pharmacokinetics: a population pharmacokinetic study. Drug Alcohol Depend. 2014;145:185\u201393.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"513_CR45","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3109\/00952990.2016.1172078","volume":"42","author":"Z Zahari","year":"2016","unstructured":"Zahari Z, et al. Relationship between ABCB1 polymorphisms and serum methadone concentration in patients undergoing methadone maintenance therapy (MMT). Am J Drug Alcohol Abuse. 2016;42(5):587\u201396.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"Pt 6","key":"513_CR46","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/000456329903600604","volume":"36","author":"J van der Weide","year":"1999","unstructured":"van der Weide J, Steijns LS. Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann Clin Biochem. 1999;36(Pt 6):722\u20139.","journal-title":"Ann Clin Biochem"},{"issue":"4","key":"513_CR47","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cpt.690","volume":"102","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther. 2017;102(4):688\u2013700.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"513_CR48","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/cpt.910","volume":"103","author":"A Gaedigk","year":"2017","unstructured":"Gaedigk A, et al. The pharmacogene variation (pharmvar) consortium: incorporation of the human cytochrome P450 (CYP) allele nomenclature database. Clin Pharmacol Ther. 2017;103(3):399\u2013401.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"513_CR49","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jcph.1","volume":"53","author":"ED Kharasch","year":"2013","unstructured":"Kharasch ED, Stubbert K. Role of cytochrome P4502B6 in methadone metabolism and clearance. J Clin Pharmacol. 2013;53(3):305\u201313.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"513_CR50","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1097\/ALN.0000000000000867","volume":"123","author":"ED Kharasch","year":"2015","unstructured":"Kharasch ED, et al. Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance, and metabolism. Anesthesiology. 2015;123(5):1142\u201353.","journal-title":"Anesthesiology"},{"issue":"4","key":"513_CR51","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1369-1600.2011.00349.x","volume":"18","author":"O Levran","year":"2013","unstructured":"Levran O, et al. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict Biol. 2013;18(4):709\u201316.","journal-title":"Addict Biol"},{"issue":"7","key":"513_CR52","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2217\/pgs.14.19","volume":"15","author":"HJ Tsai","year":"2014","unstructured":"Tsai HJ, et al. Assessment of CYP450 genetic variability effect on methadone dose and tolerance. Pharmacogenomics. 2014;15(7):977\u201386.","journal-title":"Pharmacogenomics"},{"issue":"7616","key":"513_CR53","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"M Lek","year":"2016","unstructured":"Lek M, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285\u201391.","journal-title":"Nature"},{"issue":"6","key":"513_CR54","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.clpt.2005.08.011","volume":"78","author":"S Crettol","year":"2005","unstructured":"Crettol S, et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther. 2005;78(6):593\u2013604.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"513_CR55","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/JCP.0b013e318222b5dd","volume":"31","author":"SC Wang","year":"2011","unstructured":"Wang SC, et al. CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer. J Clin Psychopharmacol. 2011;31(4):463\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"513_CR56","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/FPC.0b013e32835cb2e2","volume":"23","author":"M Dobrinas","year":"2013","unstructured":"Dobrinas M, et al. Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study. Pharmacogenet Genomics. 2013;23(2):84\u201393.","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"513_CR57","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/clpt.2010.127","volume":"88","author":"H Bunten","year":"2010","unstructured":"Bunten H, et al. OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. Clin Pharmacol Ther. 2010;88(3):383\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"513_CR58","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/ALN.0b013e3181642938","volume":"108","author":"RA Totah","year":"2008","unstructured":"Totah RA, et al. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology. 2008;108(3):363\u201374.","journal-title":"Anesthesiology"},{"issue":"1","key":"513_CR59","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/chir.10303","volume":"16","author":"JG Gerber","year":"2004","unstructured":"Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality. 2004;16(1):36\u201344.","journal-title":"Chirality"},{"issue":"2","key":"513_CR60","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0376-8716(02)00320-4","volume":"69","author":"M Shinderman","year":"2003","unstructured":"Shinderman M, et al. Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. Drug Alcohol Depend. 2003;69(2):205\u201311.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"513_CR61","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2125.2008.03312.x","volume":"67","author":"MR Shiran","year":"2009","unstructured":"Shiran MR, et al. Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol. 2009;67(1):29\u201337.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"513_CR62","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/JCP.0b013e3182664ecd","volume":"32","author":"MR Shiran","year":"2012","unstructured":"Shiran MR, et al. Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment. J Clin Psychopharmacol. 2012;32(5):666\u201371.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"513_CR63","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00004714-200104000-00016","volume":"21","author":"CB Eap","year":"2001","unstructured":"Eap CB, et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J Clin Psychopharmacol. 2001;21(2):229\u201334.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"513_CR64","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/FTD.0000000000000437","volume":"39","author":"MK Kringen","year":"2017","unstructured":"Kringen MK, et al. Combined effect of CYP2B6 genotype and other candidate genes on a steady-state serum concentration of methadone in opioid maintenance treatment. Ther Drug Monit. 2017;39(5):550\u20135.","journal-title":"Ther Drug Monit"},{"issue":"7","key":"513_CR65","doi-asserted-by":"crossref","first-page":"410","DOI":"10.5414\/CPP45410","volume":"45","author":"JK Coller","year":"2007","unstructured":"Coller JK, et al. Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone. Int J Clin Pharmacol Ther. 2007;45(7):410\u20137.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5","key":"513_CR66","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/FPC.0b013e3283386bda","volume":"20","author":"J Lotsch","year":"2010","unstructured":"Lotsch J, et al. A KCNJ6 (Kir3.2, GIRK2) gene polymorphism modulates opioid effects on analgesia and addiction but not on pupil size. Pharmacogenet Genomics. 2010;20(5):291\u20137.","journal-title":"Pharmacogenet Genomics"},{"issue":"7","key":"513_CR67","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2217\/pgs.13.58","volume":"14","author":"O Levran","year":"2013","unstructured":"Levran O, et al. Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction. Pharmacogenomics. 2013;14(7):755\u201368.","journal-title":"Pharmacogenomics"},{"key":"513_CR68","first-page":"53","volume":"5","author":"DT Barratt","year":"2012","unstructured":"Barratt DT, et al. ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics. Pharmgenomics Pers Med. 2012;5:53\u201362.","journal-title":"Pharmgenomics Pers Med"},{"issue":"3","key":"513_CR69","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/mp.2016.257","volume":"22","author":"AH Smith","year":"2017","unstructured":"Smith AH, et al. Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1. Mol Psychiatry. 2017;22(3):346\u201352.","journal-title":"Mol Psychiatry"},{"issue":"3","key":"513_CR70","doi-asserted-by":"crossref","first-page":"e1005910","DOI":"10.1371\/journal.pgen.1005910","volume":"12","author":"HC Yang","year":"2016","unstructured":"Yang HC, et al. Genome-wide pharmacogenomic study on methadone maintenance treatment identifies SNP rs17180299 and multiple haplotypes on CYP2B6, SPON1, and GSG1L associated with plasma concentrations of methadone R- and S-enantiomers in heroin-dependent patients. PLoS Genet. 2016;12(3):e1005910.","journal-title":"PLoS Genet"},{"issue":"2","key":"513_CR71","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0896-6273(00)80776-X","volume":"23","author":"T Burstyn-Cohen","year":"1999","unstructured":"Burstyn-Cohen T, et al. F-Spondin is required for accurate pathfinding of commissural axons at the floor plate. Neuron. 1999;23(2):233\u201346.","journal-title":"Neuron"},{"key":"513_CR72","doi-asserted-by":"crossref","first-page":"10873","DOI":"10.1038\/ncomms10873","volume":"7","author":"X Gu","year":"2016","unstructured":"Gu X, et al. GSG1L suppresses AMPA receptor-mediated synaptic transmission and uniquely modulates AMPA receptor kinetics in hippocampal neurons. Nat Commun. 2016;7:10873.","journal-title":"Nat Commun"},{"issue":"22","key":"513_CR73","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0024-3205(97)00160-4","volume":"60","author":"C Iribarne","year":"1997","unstructured":"Iribarne C, et al. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci. 1997;60(22):1953\u201364.","journal-title":"Life Sci"},{"issue":"1","key":"513_CR74","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1006\/abio.2002.5673","volume":"306","author":"DE Moody","year":"2002","unstructured":"Moody DE, et al. A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal Biochem. 2002;306(1):31\u20139.","journal-title":"Anal Biochem"},{"issue":"5","key":"513_CR75","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1124\/dmd.105.003681","volume":"33","author":"N Picard","year":"2005","unstructured":"Picard N, et al. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos. 2005;33(5):689\u201395.","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"513_CR76","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1038\/npp.2013.99","volume":"38","author":"RC Crist","year":"2013","unstructured":"Crist RC, et al. An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology. 2013;38(10):2003\u201310.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"513_CR77","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/tpj.2016.89","volume":"18","author":"RC Crist","year":"2018","unstructured":"Crist RC, et al. A polymorphism in the OPRM1 3\u2019-untranslated region is associated with methadone efficacy in treating opioid dependence. Pharmacogenomics J. 2018;18(1):173\u20139.","journal-title":"Pharmacogenomics J"},{"issue":"3","key":"513_CR78","doi-asserted-by":"crossref","first-page":"e0174647","DOI":"10.1371\/journal.pone.0174647","volume":"12","author":"HW Kuo","year":"2017","unstructured":"Kuo HW, et al. Pharmacogenomics study on cadherin 2 network with regard to HIV infection and methadone treatment outcome. PLoS One. 2017;12(3):e0174647.","journal-title":"PLoS One"},{"issue":"9","key":"513_CR79","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.tins.2008.07.001","volume":"31","author":"J Arikkath","year":"2008","unstructured":"Arikkath J, Reichardt LF. Cadherins and catenins at synapses: roles in synaptogenesis and synaptic plasticity. Trends Neurosci. 2008;31(9):487\u201394.","journal-title":"Trends Neurosci"},{"issue":"5","key":"513_CR80","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/mp.2015.102","volume":"21","author":"EC Nelson","year":"2016","unstructured":"Nelson EC, et al. Evidence of CNIH3 involvement in opioid dependence. Mol Psychiatry. 2016;21(5):608\u201314.","journal-title":"Mol Psychiatry"},{"issue":"3","key":"513_CR81","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF03256370","volume":"14","author":"F Fonseca","year":"2010","unstructured":"Fonseca F, et al. Response to methadone maintenance treatment is associated with the MYOCD and GRM6 genes. Mol Diagn Ther. 2010;14(3):171\u20138.","journal-title":"Mol Diagn Ther"},{"issue":"3","key":"513_CR82","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.euroneuro.2013.10.003","volume":"24","author":"F Fonseca","year":"2014","unstructured":"Fonseca F, et al. ALDH5A1 variability in opioid dependent patients could influence response to methadone treatment. Eur Neuropsychopharmacol. 2014;24(3):420\u20134.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"513_CR83","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/tpj.2010.37","volume":"11","author":"B Oneda","year":"2011","unstructured":"Oneda B, et al. beta-Arrestin2 influences the response to methadone in opioid-dependent patients. Pharmacogenomics J. 2011;11(4):258\u201366.","journal-title":"Pharmacogenomics J"},{"issue":"7","key":"513_CR84","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.pnpbp.2008.07.009","volume":"32","author":"S Crettol","year":"2008","unstructured":"Crettol S, et al. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(7):1722\u20137.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"513_CR85","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ajmg.b.30319","volume":"141B","author":"DT Barratt","year":"2006","unstructured":"Barratt DT, Coller JK, Somogyi AA. Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments. Am J Med Genet B Neuropsychiatr Genet. 2006;141B(4):323\u201331.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"513_CR86","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13722-015-0040-7","volume":"10","author":"M Bawor","year":"2015","unstructured":"Bawor M, et al. Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study. Addict Sci Clin Pract. 2015;10:19.","journal-title":"Addict Sci Clin Pract"},{"issue":"5","key":"513_CR87","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/1096-8628(20001009)96:5<592::AID-AJMG3>3.0.CO;2-Y","volume":"96","author":"BR Lawford","year":"2000","unstructured":"Lawford BR, et al. The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. Am J Med Genet. 2000;96(5):592\u20138.","journal-title":"Am J Med Genet"},{"issue":"5","key":"513_CR88","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1601-183X.2007.00386.x","volume":"7","author":"R de Cid","year":"2008","unstructured":"de Cid R, et al. BDNF variability in opioid addicts and response to methadone treatment: preliminary findings. Genes Brain Behav. 2008;7(5):515\u201322.","journal-title":"Genes Brain Behav"},{"issue":"2","key":"513_CR89","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/JCP.0000000000000082","volume":"34","author":"SC Wang","year":"2014","unstructured":"Wang SC, et al. The association of genetic polymorphisms in the kappa-opioid receptor 1 gene with body weight, alcohol use, and withdrawal symptoms in patients with methadone maintenance. J Clin Psychopharmacol. 2014;34(2):205\u201311.","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"513_CR90","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2217\/pgs.12.69","volume":"13","author":"JN Tian","year":"2012","unstructured":"Tian JN, et al. UGT2B7 genetic polymorphisms are associated with the withdrawal symptoms in methadone maintenance patients. Pharmacogenomics. 2012;13(8):879\u201388.","journal-title":"Pharmacogenomics"},{"issue":"2\u20133","key":"513_CR91","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.drugalcdep.2006.12.018","volume":"89","author":"JP de los Cobos","year":"2007","unstructured":"de los Cobos JP, et al. Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment. Drug Alcohol Depend. 2007;89(2\u20133):190\u20134.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"513_CR92","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/JCP.0000000000000698","volume":"37","author":"JP de los Cobos","year":"2017","unstructured":"de los Cobos JP, et al. Satisfaction With methadone and opioid receptor genes polymorphisms in treatment-refractory heroin-dependent patients. J Clin Psychopharmacol. 2017;37(3):378\u201380.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"513_CR93","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/tpj.2013.30","volume":"14","author":"TK Clarke","year":"2014","unstructured":"Clarke TK, et al. Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. Pharmacogenomics J. 2014;14(3):303\u20138.","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"513_CR94","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0896-6273(00)80836-3","volume":"24","author":"Y Zhu","year":"1999","unstructured":"Zhu Y, et al. Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron. 1999;24(1):243\u201352.","journal-title":"Neuron"},{"issue":"1","key":"513_CR95","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1369-1600.2012.00445.x","volume":"19","author":"EC Nelson","year":"2014","unstructured":"Nelson EC, et al. Association of OPRD1 polymorphisms with heroin dependence in a large case-control series. Addict Biol. 2014;19(1):111\u201321.","journal-title":"Addict Biol"},{"issue":"1","key":"513_CR96","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.psychres.2013.11.001","volume":"215","author":"G Gerra","year":"2014","unstructured":"Gerra G, et al. Association between gene variants and response to buprenorphine maintenance treatment. Psychiatry Res. 2014;215(1):202\u20137.","journal-title":"Psychiatry Res"},{"issue":"6","key":"513_CR97","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/add.12863","volume":"110","author":"E Evans","year":"2015","unstructured":"Evans E, et al. Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006\u201310. Addiction. 2015;110(6):996\u20131005.","journal-title":"Addiction"},{"issue":"3","key":"513_CR98","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/00952997909001723","volume":"6","author":"B Concool","year":"1979","unstructured":"Concool B, Smith H, Stimmel B. Mortality rates of persons entering methadone maintenance: a seven-year study. Am J Drug Alcohol Abuse. 1979;6(3):345\u201353.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"8","key":"513_CR99","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/jat\/bku091","volume":"38","author":"LL Richards-Waugh","year":"2014","unstructured":"Richards-Waugh LL, et al. Fatal methadone toxicity: potential role of CYP3A4 genetic polymorphism. J Anal Toxicol. 2014;38(8):541\u20137.","journal-title":"J Anal Toxicol"},{"issue":"4","key":"513_CR100","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jat\/bkw135","volume":"41","author":"T Ahmad","year":"2017","unstructured":"Ahmad T, et al. Tell-Tale SNPs: The Role of CYP2B6 in Methadone Fatalities. J Anal Toxicol. 2017;41(4):325\u201333.","journal-title":"J Anal Toxicol"},{"issue":"1","key":"513_CR101","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1369-1600.2010.00274.x","volume":"16","author":"H Bunten","year":"2011","unstructured":"Bunten H, et al. CYP2B6 and OPRM1 gene variations predict methadone-related deaths. Addict Biol. 2011;16(1):142\u20134.","journal-title":"Addict Biol"},{"issue":"6","key":"513_CR102","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1360-0443.2009.02549.x","volume":"104","author":"K Anchersen","year":"2009","unstructured":"Anchersen K, et al. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction. 2009;104(6):993\u20139.","journal-title":"Addiction"},{"issue":"3","key":"513_CR103","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1345\/aph.1G524","volume":"40","author":"JR Baker","year":"2006","unstructured":"Baker JR, et al. Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. Ann Pharmacother. 2006;40(3):392\u20136.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"513_CR104","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/00325481.2017.1270156","volume":"129","author":"SC Harris","year":"2017","unstructured":"Harris SC, et al. Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials. Postgrad Med. 2017;129(1):69\u201380.","journal-title":"Postgrad Med"},{"issue":"4","key":"513_CR105","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/10550880802324317","volume":"27","author":"MJ Krantz","year":"2008","unstructured":"Krantz MJ. Heterogeneous impact of methadone on the QTc interval: what are the practical implications? J Addict Dis. 2008;27(4):5\u20139.","journal-title":"J Addict Dis"},{"issue":"5","key":"513_CR106","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/sj.clpt.6100120","volume":"81","author":"CB Eap","year":"2007","unstructured":"Eap CB, et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther. 2007;81(5):719\u201328.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"513_CR107","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40291-015-0137-4","volume":"19","author":"JF Carlquist","year":"2015","unstructured":"Carlquist JF, et al. A Possible Mechanistic Link Between the CYP2C19 Genotype, the Methadone Metabolite Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidene (EDDP), and Methadone-Induced Corrected QT Interval Prolongation in a Pilot Study. Mol Diagn Ther. 2015;19(2):131\u20138.","journal-title":"Mol Diagn Ther"},{"issue":"10","key":"513_CR108","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1089\/omi.2012.0068","volume":"17","author":"SC Wang","year":"2013","unstructured":"Wang SC, et al. Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort. OMICS. 2013;17(10):519\u201326.","journal-title":"OMICS"},{"issue":"2","key":"513_CR109","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1124\/jpet.102.038240","volume":"303","author":"AN Katchman","year":"2002","unstructured":"Katchman AN, et al. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. J Pharmacol Exp Ther. 2002;303(2):688\u201394.","journal-title":"J Pharmacol Exp Ther"},{"key":"513_CR110","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugalcdep.2014.04.027","volume":"141","author":"A Hajj","year":"2014","unstructured":"Hajj A, et al. KCNH2 polymorphism and methadone dosage interact to enhance QT duration. Drug Alcohol Depend. 2014;141:34\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"513_CR111","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/07853890802668530","volume":"41","author":"A Marjamaa","year":"2009","unstructured":"Marjamaa A, et al. High prevalence of four long QT syndrome founder mutations in the Finnish population. Ann Med. 2009;41(3):234\u201340.","journal-title":"Ann Med"},{"issue":"10","key":"513_CR112","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.euroneuro.2012.02.002","volume":"22","author":"SC Wang","year":"2012","unstructured":"Wang SC, et al. Genetic polymorphisms in the opioid receptor mu1 gene are associated with changes in libido and insomnia in methadone maintenance patients. Eur Neuropsychopharmacol. 2012;22(10):695\u2013703.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"513_CR113","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/02791072.2017.1290303","volume":"49","author":"A Sharafshah","year":"2017","unstructured":"Sharafshah A, et al. Association of OPRD1 gene variants with opioid dependence in addicted male individuals undergoing methadone treatment in the North of Iran. J Psychoactive Drugs. 2017;49(3):242\u201351.","journal-title":"J Psychoactive Drugs"},{"issue":"4","key":"513_CR114","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/10550887.2017.1361724","volume":"36","author":"A Albonaim","year":"2017","unstructured":"Albonaim A, et al. Association of OPRK1 gene polymorphisms with opioid dependence in addicted men undergoing methadone treatment in an Iranian population. J Addict Dis. 2017;36(4):227\u201335.","journal-title":"J Addict Dis"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-018-0513-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0513-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0513-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T01:39:07Z","timestamp":1612834747000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-018-0513-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":114,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["513"],"URL":"https:\/\/doi.org\/10.1007\/s40263-018-0513-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"5 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr Crist was supported by National Institute on Drug Abuse grant K01 DA036751. Dr Clarke is funded by the Wellcome Trust (Wellcome Trust Strategic Award \u2018STratifying Resilience and Depression Longitudinally\u2019 [STRADL] Reference 104036\/Z\/14\/Z). Dr Berrettini was supported by National Institute on Drug Abuse grant R01 DA044015. The funding sources had no role in preparation, review, or approval of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Drs Crist, Clarke, and Berrettini declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}